Condition
Appendix Adenocarcinoma
Total Trials
3
Recruiting
1
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Active Not Recruiting1
Completed1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03074513Phase 2Active Not RecruitingPrimary
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
NCT03108131Phase 2Completed
Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors
NCT05734430Recruiting
Genetics of Appendix Cancer Study
Showing all 3 trials